Clinical data in 10 CML patients treated with BMT
| Patient No. . | Sex/Age at Diagnosis . | Gratwohl's Score . | Karyotype at Presentation [% Cell Ph+] . | Therapy Before BMT . | Duration of Follow-Up (mos) . | Duration of CCR (mos) . |
|---|---|---|---|---|---|---|
| 12 | F/44 | 3 | t(9;22)(q34;q11) [95%] | HU, IFN-α2b, Ara-c | 32 | 4 |
| 13 | M/22 | 2 | t(9;22)(q34;q11) [100%] | HU, splenectomy | 56 | 65 |
| 14 | F/28 | 0 | t(9;22)(q34;q11) [54%] | HU, IFN-α2a | 95 | 36 |
| 15 | M/35 | 3 | t(9;22)(q34;q11)del(7)(p11p21) [100%] | HU, IFN-α2b, Ara-c | 37 | 12 |
| 16 | F/15 | 0 | t(9;22)(q34;q11) [81%] | HU, IFN-α2a | 40 | 24 |
| 17 | F/48 | 2 | t(9;22)(q34;q11) [100%] | HU, IFN-α2b | 47 | 24 |
| 18 | F/34 | 1 | t(9;22)(q34;q11) [100%] | HU | 76 | 60 |
| 19 | F/28 | 1 | t(9;22)(q34;q11) [100%] | HU | 29 | 18 |
| 20 | M/13 | 2 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2b | 84 | 44 |
| 21 | F/41 | 3 | t(9;22)(q34;q11) [97%] | HU, IFN-α2b, Ara-c | 47 | 24 |
| Patient No. . | Sex/Age at Diagnosis . | Gratwohl's Score . | Karyotype at Presentation [% Cell Ph+] . | Therapy Before BMT . | Duration of Follow-Up (mos) . | Duration of CCR (mos) . |
|---|---|---|---|---|---|---|
| 12 | F/44 | 3 | t(9;22)(q34;q11) [95%] | HU, IFN-α2b, Ara-c | 32 | 4 |
| 13 | M/22 | 2 | t(9;22)(q34;q11) [100%] | HU, splenectomy | 56 | 65 |
| 14 | F/28 | 0 | t(9;22)(q34;q11) [54%] | HU, IFN-α2a | 95 | 36 |
| 15 | M/35 | 3 | t(9;22)(q34;q11)del(7)(p11p21) [100%] | HU, IFN-α2b, Ara-c | 37 | 12 |
| 16 | F/15 | 0 | t(9;22)(q34;q11) [81%] | HU, IFN-α2a | 40 | 24 |
| 17 | F/48 | 2 | t(9;22)(q34;q11) [100%] | HU, IFN-α2b | 47 | 24 |
| 18 | F/34 | 1 | t(9;22)(q34;q11) [100%] | HU | 76 | 60 |
| 19 | F/28 | 1 | t(9;22)(q34;q11) [100%] | HU | 29 | 18 |
| 20 | M/13 | 2 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2b | 84 | 44 |
| 21 | F/41 | 3 | t(9;22)(q34;q11) [97%] | HU, IFN-α2b, Ara-c | 47 | 24 |
CML indicates chronic myeloid leukemia; BMT, bone marrow transplantation; HU, hydroxyurea; IFN, interferon; Ara-c, cytosine arabinoside; BU, busulfan; CCR, complete cytogenetic remission.